WO2025195449 - ANTI-EGFR/PTK7 ANTIBODIES AND USES THEREOF

National phase entry is expected:
Publication Number WO/2025/195449
Publication Date 25.09.2025
International Application No. PCT/CN2025/083688
International Filing Date 20.03.2025
Title **
[English] ANTI-EGFR/PTK7 ANTIBODIES AND USES THEREOF
[French] ANTICORPS ANTI-EGFR/PTK7 ET LEURS UTILISATIONS
Applicants **
BIOCYTOGEN PHARMACEUTICALS (BEIJING) CO., LTD.
Inventors
SHANG, Chengzhang
LI, Zhuolin
ZHANG, Na
YANG, Yi
SHEN, Yuelei
Priority Data
PCT/CN2024/082933   21.03.2024   CN
PCT/CN2024/096627   31.05.2024   CN
PCT/CN2024/121726   27.09.2024   CN
Application details
Total Number of Claims/PCT *
Number of Independent Claims *
Number of Priorities *
Number of Multi-Dependent Claims *
Number of Drawings *
Pages for Publication *
Number of Pages with Drawings *
Pages of Specification *
*
Number of Office Actions *
*
International Searching Authority
*
Recordal of a Change of the Applicant's Name/Address
*
Type of Assignment
*
Applicant's Legal Status
*
*
*
*
*
*
Entry into National Phase under
*
Patent Delivery
*
Translation

* The data is based on automatic recognition. Please verify and amend if necessary.

** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.

Quotation for National Phase entry

Country StagesTotal
China Filing, Examination, Granting3361
EPO Filing, Examination, Granting29778
Japan Filing, Examination, Granting3110
South Korea Filing, Examination, Granting4250
USA Filing, Examination, Granting15190
MasterCard Visa
Total: 55,689
Contact Us
Abstract[English] This disclosure relates to anti-EGFR/PTK7 antibodies, and antibody drug conjugates derived therefrom, and the use thereof.[French] La présente invention concerne des anticorps anti-EGFR/PTK7, et des conjugués anticorps-médicament dérivés de ceux-ci, et leur utilisation.